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Human somatic cell nuclear transfer (SCNT) holds great potential in regenerative medicine; however, its
applicability has been limited by great variability in reprogramming efficiencies. A new study in this issue
of Cell Stem Cell reports a simple way to expand human SCNT to hard-to-reprogram oocytes (Chung
et al., 2015).In 1962, Sir John Gurdon demonstrated
that an enucleated Xenopus egg was
capable of reprogramming a somatic cell
nucleus back to an embryonic state and
give rise to a fully functional tadpole (Gur-
don, 1962). This discovery revolutionized
our understanding of cell fate and devel-
opment, as it proved for the first time
that differentiation is not a point of no-
return in the life of a cell. Since this pio-
neering work, the process of SCNT, or
cloning, has been successfully applied
to various animals. However, it wasn’t un-
til very recently that human SCNT was
accomplished, thanks to technical ad-
vances and protocol optimization pro-
vided by the Mitalipov group (Tachibana
et al., 2013). While this represented a
great leap forward toward the potential
application of SCNT to human regenera-
tive medicine, variable reprogramming ef-
ficiencies and restriction of successful
SCNT to oocytes of the highest quality
has limited the widespread use of human
SCNT.
In SCNT, after the nucleus of an oocyte
is replaced by the nucleus of a somatic
cell and the resulting diploid oocyte (NT-
oocyte) is activated, the NT-oocyte be-
gins to divide and eventually forms a blas-
tocyst. However, only embryos derived
from high-quality oocytes have the ability
to progress to the blastocyst stage and
successfully generate SCNT-derived hu-
man embryonic stem cell (NT-hESC) lines
(Tachibana et al., 2013; Chung et al.,
2014; Yamada et al., 2014). While it is still
not clear what determines the quality and
reprogramming efficiency of an oocyte, it
has been repeatedly observed that oo-
cytes from certain donors reprogram
more efficiently than those from other do-
nors (Tachibana et al., 2013; Chung et al.,2014; Yamada et al., 2014). Two factors
that may play a role are the length of the
hormonal treatment required for oocyte
maturation and the age of the donor, with
longer treatments (11–13 days) and older
age (27–32 years old) negatively affecting
thedevelopmental potential ofNToocytes
(Yamada et al., 2014). However, further
identification of molecular markers of
oocyte quality as well as ways to increase
quality represent an essential step toward
expansion of SCNT applicability and
reproducibility.
Chung et al. (2015), in this issue of Cell
Stem Cell, report an improvement of
human SCNT reprogramming efficiencies
by simply injecting mRNA encoding a his-
tone demethylase, KDM4A. This new pro-
tocol allows the generation of NT-hESCs
from lower quality oocytes that had previ-
ously failed to reprogram using classic
SCNT protocols.
To understand if intrinsic properties
of NT-embryos interfere with their ability
to progress in development, the study
initially compared NT-embryos and em-
bryos generated by in vitro fertilization
(IVF) that normally advance to blastocyst
at high rates. As embryonic gene tran-
scription begins by the eight-cell stage in
humans (Telford et al., 1990), RNA-seq
analysis of the eight-cell embryo tran-
scriptome was performed on embryos
from the two groups. Examination of the
status of 707 human zygotic activation re-
gions revealed that 45% of these (318
of 707) failed to activate in NT-embryos.
These regions, called ‘‘reprogramming-
resistant regions’’ (RRRs), were found to
be enriched for the histone H3 lysine 9 tri-
methylation (H3K9me3) mark and to be
less sensitive to DNaseI, thus suggesting
a heterochromatic signature. The findingCell Stem Cell 17,is reminiscent of what was previously
observed in mouse SCNT, where persis-
tent H3K9me3 in the embryo genome
constitutes a barrier to SCNT (Matoba
et al., 2014). Therefore, the authors
sought to identify a demethylase that
would remove the H3K9me3 mark from
RRRs and thus facilitate reprogramming.
The demethylase Kdm4d had been
previously shown to lower the levels of
H3K9me3 in mouse NT-embryos, and
this helped overcome the reprogramming
barrier observed in that system (Matoba
et al., 2014). Therefore, the authors tested
if the same was true using the corre-
sponding human homolog, the KDM4
family of demethylases. Intriguingly, injec-
tion of activated NT-oocytes with human
demethylase KDM4A mRNA, which re-
duces H3K9me3 levels in mouse NT-em-
bryos, increased the portion of activated
RRRs by almost 50% (158 of 318).
Indeed, KDM4A-expressing NT embryos
were able to more efficiently advance
to the late blastocyst stage (14.3%
compared to 0% for classically derived
NT-embryos) and to successfully give
rise to NT-hESC lines.
The current study therefore establishes
an improved method to generate human
NT-hESC lines using apparently low-
quality oocytes that had previously failed
the classic SCNT protocol. Given the
limited availability of mature oocytes, this
improvement will allow for a more wide-
spread utilization of human SCNT and
has the potential to significantly expand
the applicability of SCNT to the field of
therapeutic and regenerative medicine.
While the new method requires injection
of KDM4A mRNA, identification of com-
pounds that lead to increased levels
and/or activity of endogenous KDM4ADecember 3, 2015 ª2015 Elsevier Inc. 641
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Previewswill significantly limit oocyte/embryo
manipulation, streamline the protocol,
and allow for better, more standardized
reprogramming. Additionally, isolation of
H3K9 methyltransferase inhibitors might
also help reprogramming efficiencies by
reducing the starting levels of H3K9me3
marks in somatic cells before SCNT.
Indeed, knockdown of the Suv39h1 and
Suv39h2 methyltransferases in mouse
embryonic fibroblasts globally reduced
H3K9me3 levels and improved SCNT effi-
ciencies (Matoba et al., 2014).
Finally, it is tempting to speculate that
other epigenetic modulators have the
potential of further improving reprogram-
ming efficiencies, given the fact that about642 Cell Stem Cell 17, December 3, 2015 ª2half of RRRs remain inactive even in the
presence of KDM4A (160 of 318 regions).
Moreover, a global comparison of NT-
and IVF-embryos past the eight-cell stage
might reveal other differences that pre-
vent NT-embryos from advancing to blas-
tocysts. Together, the elucidation of these
molecular pathways will not only greatly
contribute to our general understanding
of reprogramming but will also shed light
on early human development.
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Cohesin complex components are frequently mutated in human myeloid cancers. Three new studies
now show that cohesin mutations disrupt the differentiation of normal hematopoietic stem and progenitor
cells and enhance self-renewal, shedding light on how these alterations may contribute to leukemic
transformation.Genes coding for cohesin complex mem-
bers (i.e., SMC1A, SMC3, RAD21, and
STAG2) are recurrently mutated in pa-
tients with myeloid cancers such as acute
myeloid leukemia (AML), myelodysplasia,
chronic myelomonocytic leukemia, and
the transient abnormal myelopoiesis of
Down syndrome. STAG2 and RAD21 are
predominantly targeted by nonsense,
frameshift, or splice site mutations,
whereas SMC1A and SMC3 are predom-
inantly targeted by missense mutations
(Figure 1). Mutations are heterozygous,
but those targeting STAG2 and SMC1A
may be functionally homozygous given
the genes’ X chromosome location. The
presence of mutations is typically mutu-
ally exclusive between subunits. Interest-
ingly, cohesin mutations are on occasion
observed in the blood of normal aging hu-
mans without hematological malignancy,
raising the possibility that they may pro-mote a pre-leukemic stem cell state that
is predisposed toward transformation
(Kon et al., 2013; Cancer Genome Atlas
Research Network, 2013; Losada, 2014;
Jaiswal et al., 2014). Three recent reports,
one in Cell Stem Cell (Mazumdar et al.,
2015) and two in The Journal of Experi-
mental Medicine (Viny et al., 2015; Mul-
lenders et al., 2015), now describe how
such mutations may alter normal hemato-
poietic stem and progenitor cell (HSPC)
function to promote transformation.
The cohesin complex is essential in
mammalian biology. Smc3 and Rad21
null mice exhibit early embryonic lethality,
and humans with Cornelia de Lange syn-
drome (a syndrome of developmental
retardation with facial and skeletal abnor-
malities) have mutations in the cohesin
loading factor NIPBL or cohesin complex
components (Losada, 2014). Function-
ally, the complex forms a ring-like struc-ture encircling sister chromatin fibers.
During mitosis, cohesin links sister chro-
matids to facilitate proper chromosome
segregation and post-replicative DNA
repair. Outside of its roles in mitosis, co-
hesin co-occupies active promoters and
enhancers with RNA polymerase and
Mediator and promotes enhancer-pro-
moter DNA looping. It also contributes to
the topological organization of the
genome through interactions with CTCF,
stabilizes the binding of transcription fac-
tors to low-affinity DNA motifs, organizes
chromatin looping at DNA replication fac-
tories, and sustains DNA accessibility for
transcription factor binding through cell
division to provide a cellular memory of
transcriptional states (Losada, 2014).
The three new reports have explored
the outcomes of cohesin depletion or mu-
tation in the pathogenesis of myeloid ma-
lignancy. Reporting in Cell Stem Cell,
